<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554398</url>
  </required_header>
  <id_info>
    <org_study_id>INTEGRAL</org_study_id>
    <nct_id>NCT00554398</nct_id>
  </id_info>
  <brief_title>Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression</brief_title>
  <official_title>Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An intensification with the HIV-1 integrase inhibitor Raltegravir (RAL) of a stable HAART
      regimen with persistent HIV-1 viral suppression could increase the slope of decay of the
      HIV-1 latent reservoir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While highly active antiretroviral therapy (HAART) reduces plasma HIV-1 levels to below the
      limits of detection with standard assays, replication-competent virus persist in a stable,
      latent reservoir in resting CD4+ T cells. So, there is a rapid resumption in plasma viremia
      when therapy is interrupted.

      In addition to cellular reservoir, other pharmacologically privileged areas such as the
      central nervous system and the genital tract might act as additional sources of residual
      virus in patients with undetectable levels of plasma HIV-1 RNA. There is great current
      interest in strategies for depleting and eliminating this reservoir.

      The antiviral potency of current regimens emerges as an important determinant of complete
      viral control. In certain patients, the latent reservoir decay can be hastened with treatment
      intensification.

      An intensification with the HIV-1 integrase inhibitor Raltegravir (RAL) of a stable HAART
      regimen with persistent HIV-1 viral suppression could increase the slope of decay of the
      HIV-1 latent reservoir. This could provide further insight into this area, decrease the size
      of latent reservoir, and translate into clinical benefits for patients being simplified to
      maintenance monotherapy with RAL or in the HIV-1 rebound kinetics and slope after a
      programmed treatment interruption.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of integrated and unintegrated viral HIV-1 DNA in PBMCs</measure>
    <time_frame>Basal, week 12, week 24 and week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of residual HIV-1 (using an ultrasensitive RT-PCR assay with a lower limit of quantification of 5 copies/mL)</measure>
    <time_frame>Basal, week 1, week 2, week 4, week 8, week 12, week 24, week 36 and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blips during the study (&gt; 50 copies/mL, preceded and followed by determinations &lt; 50 copies/mL in previous and posterior controls)</measure>
    <time_frame>Basal, week 4, week 8, week 12, week 24, week 36 and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte activation marker CD8+HLADR+CD38+</measure>
    <time_frame>Basal, week 2, week 4, week 12, week 24 and week 48.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir plasma trough concentration.</measure>
    <time_frame>Week 12, week 24 and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of apoptosis in CD4 and CD8 T cells.</measure>
    <time_frame>Week 48 and week 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-0518 400mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0518 400mg twice a day</intervention_name>
    <description>Raltegravir, MK-0518</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Raltegravir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infected adults (+18 years old).

          2. Complete virological suppression (&lt;50 copies/mL) for += 12 months, including at least
             3 times during the last year.

          3. Patients on HAART regimen including a PI or an NNRTI and at least two nucleotide
             inhibitors.

          4. Voluntary written informed consent.

        Exclusion Criteria:

          1. Pregnancy, or fertile women willing to be pregnant.

          2. Active substance abuse or major psychiatric disease.

          3. Presence of drug-related mutations or any polymorphism or mutation associated to
             MK-0518 resistance prior to first HAART (only if genotype is available).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martínez-Picado Javier, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irsi Caixa -Hospital Germans Trias i Pujol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paredes Roger, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clotet Bonaventura, MS,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Llibre Josep Mª, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lluita contra la SIDA Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic I Provinical de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2007</study_first_submitted>
  <study_first_submitted_qc>November 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <last_update_submitted>November 12, 2009</last_update_submitted>
  <last_update_submitted_qc>November 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>LLuita Sida Foundation</name_title>
    <organization>LLuita Sida Foundation</organization>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>MK-0518</keyword>
  <keyword>Treatment intensification</keyword>
  <keyword>HIV-1 latency</keyword>
  <keyword>HIV eradication</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

